Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, by Drug Type (HPV Therapeutics (Immunomodulatory Agents, Keratolytic Agents, Anti-Neoplastic Agents, and Sinecatechins) and CMV Therapeutics (Ganciclovir/Valaganciclovir, Foscarnet, and  Cidifovir), by Application (HPV Therapeutics- Genital warts, Cervical cancer, Epidermodysplasia Verrucifdormis, and Others) and (CMV Therapeutics-CMV Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

  • Published On : Jun 2019 |
  • Pages : 167 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market Insights

Human papillomavirus (HPV) and Cytomegalovirus (CMV) are viral pathogens. HPV is a different virus than HIV (Human Immunodeficiency Virus) and HSV (Herpes Simplex Virus). HPV causes sexually transmitted infection. HPV is a major cause of cervical, vulva, vagina, penis, anus, mouth, and throat cancer. CMV is the most common herpesvirus infection. These infections can spread through sexual and non-sexual contact with body secretions (fluids).

The global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market was valued at US$ 3,006.4 million in 2018, and is expected to witness a CAGR of 6.0% during the forecast period (2018– 2026).

Figure 1. Global Human Papillomavirus (HPV) and (CMV) Cytomegalovirus Therapeutics Market Value Analysis (US$ Mn) and Y-o-Y Growth (%)

HPV & CMV Therapeutics  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing number of sexually transmitted infections is expected to drive growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market

Increasing number of sexually transmitted infections is one of major drivers for the market growth. For instance, according to World Health Organization’s (WHO) report in 2019, over 290 million women suffer from HPV infection worldwide, annually and over 1 million people suffer from sexually transmitted infections (STIs) every day, worldwide.

Moreover, increasing approvals for vaccines is expected to boost the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market growth. For instance, in October 2018, the U.S Food and Drug Administration (FDA) approved Gardasil 9 ( HPV 9-valent vaccine), developed by Merck & Co., Inc. Gardasil 9 is used for cervical, vulvar, vaginal, and anal cancers caused by HPV types.

Global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market- Regional Analysis

Regional segmentation of the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market is expected to account for the largest market share, owing to increasing initiatives for treatment of cervical cancer by health regulatory authorities in this region. For instance, in November 2018, the Pan American Health Organization (PAHO) launched its Communication Campaign with the slogan, ‘Don’t let cervical cancer stop you’. The aim of the campaign was to create awareness among the people for prevention of cervical cancer (caused by HPV infection).

Furthermore, Asia Pacific is projected to witness significant growth in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market during the forecast period, owing to increasing partnership of hospitals for the treatment of cervical cancer. For instance, in May 2019, Parirenyatwa Hospital (Zimbabwe’s largest referral hospitalannounced its partnership with China's Hunan Provincial Maternal Hospital. Under this partnership, both hospitals offer free cervical cancer screening and treatment to women in Zimbabwe.

Europe is also expected to gain significant share in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market over the forecast period, attributed to increasing products upgrade by key players. For instance, in March 2015, Fujirebio Europe upgraded its HPV genotyping panel with the launch of its new INNO-LiPA HPV Genotyping Extra II assay. It is used for HPV type specific patient monitoring and cervical cancer treatment.

Figure 2: Global Human Papillomavirus (HPV) and (CMV) Cytomegalovirus Therapeutics Market Value (US$ Mn), By Region, 2018

HPV & CMV Therapeutics  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market - Competitive Landscape

Key players operating in the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market include, Allergan, Bausch Health, GlaxoSmithKline, Lee’s Pharmaceutical Holdings, Merck Sharp & Dohme, Fougera Pharmaceuticals, Clinigen Group plc, Perrigo Company plc, Roche Holding AG, Biotest AG, and Fresenius Kabi.

Cytomegalovirus (CMV) infections spread through body fluids such as saliva, semen, breast milk, and urine. Signs and symptoms of the infections include, fatigue, fever, diarrhea, pneumonia, and hepatitis, shortness of breath, gastrointestinal ulceration, and bleeding.

Although no treatment for the infection caused by human papillomavirus (HPV) is available, symptoms can be treated. Most sexually active men and women suffer from HPV infections. The infections spread through oral, vaginal or anal sex. HPV can also be transmitted during birth to infant and can lead to genital or respiratory infections.

Market Dynamics

Increasing collaboration activities of major players is expected to propel growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market. For instance, in November 2018, GeoVax Labs Inc. announced collaboration with Virometix. The collaboration focuses on development of therapeutic vaccines for HPV infections. This collaboration will include preclinical animal testing of GeoVax’s MVA-Vectored HPV vaccines candidates in combination with Virometix synthetic HPV vaccines candidates.

Moreover, increasing regulatory approvals for novel therapies is expected to boost the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market growth. For instance, in November 2017, Merck received the U.S. Food and Drug Administration approval for its Prevymis (letermovir) tablets and intravenous (IV) injection for prophylaxis of CMV infections and CMV seropositive recipients.

Key features of the study:

  • This report provides in-depth analysis of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market size (US$ Mn), and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, , Allergan, Bausch Health, GlaxoSmithKline, Lee’s Pharmaceutical Holdings, Merck Sharp & Dohme, Fougera Pharmaceuticals, Clinigen Group plc., Perrigo Company plc., Roche Holding AG, Biotest AG, and Fresenius Kabi
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for anesthesia device market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Drug Type:
    • HPV Therapeutics
      • Immunomodulatory Agents
        • Interleukins
        • Cytokines
        • Chemokine
        • Others
      • Keratolytic Agents
        • TCA (Trichloroacetic Acid)
        • Bichloracetic Acid
      • Anti-neoplastic Agents
      • Sinecatechins
    • CMV Therapeutics
      • Ganciclovir/Valganciclovir
      • Foscarnet
      • Cidifovir
    • Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Application:
      • HPV Therapeutics Application
        • Genital warts
        • Cervical cancer
        • Epidermodysplasia Verrucifdormis
        • Others
      • CMV Therapeutics Application
        • CMV Retinitis
        • Pneumonia
        • Gastrointestinal ulcers
        • Encephalitis
        • Others
      • Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
    • By Drug Type:
      • HPV Therapeutics
        • Immunomodulatory Agents
          • Interleukins
          • Cytokines
          • Chemokine
          • Others
        • Keratolytic Agents
          • TCA (Trichloroacetic Acid)
          • Bichloracetic Acid
        • Anti-neoplastic Agents
        • Sinecatechins
      • CMV Therapeutics
        • Ganciclovir/Valganciclovir
        • Foscarnet
        • Cidifovir
    • By Application
      • HPV Therapeutics Application
        • Genital warts
        • Cervical cancer
        • Epidermodysplasia Verrucifdormis
        • Others
      • CMV Therapeutics Application
        • CMV Retinitis
        • Pneumonia
        • Gastrointestinal ulcers
        • Encephalitis
        • Others
    • By Distribution Channel:
      • Hospitals Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
    • By Drug Type:
      • HPV Therapeutics
        • Immunomodulatory Agents
          • Interleukins
          • Cytokines
          • Chemokine
          • Others
        • Keratolytic Agents
          • TCA (Trichloroacetic Acid)
          • Bichloracetic Acid
        • Anti-neoplastic Agents
        • Sinecatechins
      • CMV Therapeutics
        • Ganciclovir/Valganciclovir
        • Foscarnet
        • Cidifovir
    • By Application
      • HPV Therapeutics Application
        • Genital warts
        • Cervical cancer
        • Epidermodysplasia Verrucifdormis
        • Others
      • CMV Therapeutics Application
        • CMV Retinitis
        • Pneumonia
        • Gastrointestinal ulcers
        • Encephalitis
        • Others
    • By Distribution Channel:
      • Hospitals Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
  • Asia Pacific
    • By Country:
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
    • By Drug Type:
      • HPV Therapeutics
        • Immunomodulatory Agents
          • Interleukins
          • Cytokines
          • Chemokine
          • Others
        • Keratolytic Agents
          • TCA (Trichloroacetic Acid)
          • Bichloracetic Acid
        • Anti-neoplastic Agents
        • Sinecatechins
      • CMV Therapeutics
        • Ganciclovir/Valganciclovir
        • Foscarnet
        • Cidifovir
    • By Application
      • HPV Therapeutics Application
        • Genital warts
        • Cervical cancer
        • Epidermodysplasia Verrucifdormis
        • Others
      • CMV Therapeutics Application
        • CMV Retinitis
        • Pneumonia
        • Gastrointestinal ulcers
        • Encephalitis
        • Others
    • By Distribution Channel:
      • Hospitals Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • By Drug Type:
      • HPV Therapeutics
        • Immunomodulatory Agents
          • Interleukins
          • Cytokines
          • Chemokine
          • Others
        • Keratolytic Agents
          • TCA (Trichloroacetic Acid)
          • Bichloracetic Acid
        • Anti-neoplastic Agents
        • Sinecatechins
      • CMV Therapeutics
        • Ganciclovir/Valganciclovir
        • Foscarnet
        • Cidifovir
    • By Application
      • HPV Therapeutics Application
        • Genital warts
        • Cervical cancer
        • Epidermodysplasia Verrucifdormis
        • Others
      • CMV Therapeutics Application
        • CMV Retinitis
        • Pneumonia
        • Gastrointestinal ulcers
        • Encephalitis
        • Others
    • By Distribution Channel:
      • Hospitals Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • By Drug Type:
      • HPV Therapeutics
        • Immunomodulatory Agents
          • Interleukins
          • Cytokines
          • Chemokine
          • Others
        • Keratolytic Agents
          • TCA (Trichloroacetic Acid)
          • Bichloracetic Acid
        • Anti-neoplastic Agents
        • Sinecatechins
      • CMV Therapeutics
        • Ganciclovir/Valganciclovir
        • Foscarnet
        • Cidifovir
    • By Application
      • HPV Therapeutics Application
        • Genital warts
        • Cervical cancer
        • Epidermodysplasia Verrucifdormis
        • Others
      • CMV Therapeutics Application
        • CMV Retinitis
        • Pneumonia
        • Gastrointestinal ulcers
        • Encephalitis
        • Others
    • By Distribution Channel:
      • Hospitals Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
    • By Drug Type:
      • HPV Therapeutics
        • Immunomodulatory Agents
          • Interleukins
          • Cytokines
          • Chemokine
          • Others
        • Keratolytic Agents
          • TCA (Trichloroacetic Acid)
          • Bichloracetic Acid
        • Anti-neoplastic Agents
        • Sinecatechins
      • CMV Therapeutics
        • Ganciclovir/Valganciclovir
        • Foscarnet
        • Cidifovir
    • By Application
      • HPV Therapeutics Application
        • Genital warts
        • Cervical cancer
        • Epidermodysplasia Verrucifdormis
        • Others
      • CMV Therapeutics Application
        • CMV Retinitis
        • Pneumonia
        • Gastrointestinal ulcers
        • Encephalitis
        • Others
    • By Distribution Channel:
      • Hospitals Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
  • Company Profiles
    • GlaxoSmithKline*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Allergan
    • Bausch Health
    • Lee’s Pharmaceutical Holdings
    • Merck Sharp & Dohme
    • Fougera Pharmaceuticals
    • Clinigen Group plc.
    • Perrigo Company plc.
    • Roche Holding AG
    • Biotest AG
    • Fresenius Kabi

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Epidemiology
    • Technology Advancements
    • Patent Analysis
    • Adherence Rate
    • Product Switch (U.S.)
    • Historical Overview
    • Merger and Acquisition
    • Regulatory and Reimbursement Scenario
    • PORTER’S Five Forces
    • PEST Analysis
  4. Global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market By Drug Type, 2018 – 2026, (US$ Million)
    •  Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • HPV  Therapeutics
      • Immunomodulatory Agents
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
          • Interleukins
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
          • Cytokines
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
          • Chemokine
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
          • Others
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
      • Keratolytic Agents
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
          • TCA
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
          • Bichloracetic Acid
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
      • Anti-neoplastic Agents
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
          • Sinecatechins
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • CMV Therapeutics
      • Ganciclovir/ Valaganciclovir
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
          • Foscarnet
            • Introduction
            • Market Size and Forecast , and Y-o-Y Growth, 2016 – 2026, (US$ Million)
          • Cidifovir
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  5. Global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, By Application, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • HPV Therapeutics Application
      • Genital warts
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
      • Cervical cancer
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
      • Epidermodysplasia Verrucifdormis
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
      • Others
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • CMV Therapeutics Application
      • CMV Retinitis
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
      • Pneumonia
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
      • Gastrointestinal ulcers
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
      • Encephalitis
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
      • Others
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  6. Global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, By Distribution Chanel, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  7. Global Human Papillomavirus (HPV) and Cytomegalovirus (CMV)  Market, By Region, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • GlaxoSmithKline
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • ALLERGAN
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bausch Health
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Lee’s Pharmaceuticals Holdings
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck Sharp & Dohme
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Fougera Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Clinigen Group plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Perrigo Company plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Roche Holdings AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Fresenius Kabi
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 37 market data tables and 33 figures on “human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market” - Global forecast to 2026”

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.